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Background: External pilot or feasibility studies can be used to estimate key unknown parameters to inform the
design of the definitive randomised controlled trial (RCT). However, there is little consensus on how large pilot
studies need to be, and some suggest inflating estimates to adjust for the lack of precision when planning the
definitive RCT.
Methods: We use a simulation approach to illustrate the sampling distribution of the standard deviation for
continuous outcomes and the event rate for binary outcomes. We present the impact of increasing the pilot
sample size on the precision and bias of these estimates, and predicted power under three realistic scenarios. We
also illustrate the consequences of using a confidence interval argument to inflate estimates so the required power
is achieved with a pre-specified level of confidence. We limit our attention to external pilot and feasibility studies
prior to a two-parallel-balanced-group superiority RCT.
Results: For normally distributed outcomes, the relative gain in precision of the pooled standard deviation (SDp)
is less than 10% (for each five subjects added per group) once the total sample size is 70. For true proportions
between 0.1 and 0.5, we find the gain in precision for each five subjects added to the pilot sample is less than 5%
once the sample size is 60. Adjusting the required sample sizes for the imprecision in the pilot study estimates can
result in excessively large definitive RCTs and also requires a pilot sample size of 60 to 90 for the true effect sizes
considered here.
Conclusions: We recommend that an external pilot study has at least 70 measured subjects (35 per group) when
estimating the SDp for a continuous outcome. If the event rate in an intervention group needs to be estimated by
the pilot then a total of 60 to 100 subjects is required. Hence if the primary outcome is binary a total of at least 120
subjects (60 in each group) may be required in the pilot trial. It is very much more efficient to use a larger pilot
study, than to guard against the lack of precision by using inflated estimates.
Keywords: sample size, feasibility studies, pilot studies, binary outcomes, continuous outcomes, RCTsBackground
In 2012/13, the National Institute for Health Research
(NIHR) funded £208.9 million of research grants across
a broad range of programmes and initiatives to ensure
that patients and the public benefit from the most cost-
effective up-to-date health interventions and treatments
as quickly as possible [1]. A substantial proportion of
these research grants were randomised controlled trials* Correspondence: m.d.teare@sheffield.ac.uk
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unless otherwise stated.(RCTs) to assess the clinical effectiveness and cost-
effectiveness of new health technologies. Well-designed
RCTs are widely regarded as the least biased research
design for evaluating new health technologies and decision-
makers, such as the National Institute for Health and Care
Excellence (NICE), are increasingly looking to the results of
RCTs to guide practice and policy.
RCTs aim to provide precise estimates of treatment ef-
fects and therefore need to be well designed to have
good power to answer specific clinically important ques-
tions. Both overpowered and underpowered trials aretd. This is an Open Access article distributed under the terms of the Creative
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and practical problems. Good trial design requires the
magnitude of the clinically important effect size to be
stated in advance. However, some knowledge of the po-
pulation variation of the outcome or the event rate in
the control group is necessary before a robust sample size
calculation can be done. If the outcome is well established,
these key population or control parameters can be esti-
mated from previous studies (RCTs or cohort studies) or
through meta-analyses. However, in some cases finding
robust estimates can pose quite a challenge if reliable data,
for the proposed trial population under investigation, do
not already exist.
A systematic review of published RCTs with continuous
outcomes found evidence that the population variation
was underestimated (in 80% of reported endpoints) in the
sample size calculations compared to the variation ob-
served when the trial was completed [2]. This study also
found that 25% of studies were vastly underpowered and
would have needed five times the sample size if the vari-
ation observed in the trial had been used in the sample
size calculation. A more recent review of trials with both
binary and continuous outcomes [3] found that there was
a 50% chance of underestimating key parameters. How-
ever, they too found large differences between the esti-
mates used in the sample size calculation compared to the
estimates derived from the definitive trial. This suggests
that many RCTs are indeed substantially underpowered or
overpowered. A systematic review of RCT proposals rea-
ching research ethics committees [4] found more than half
of the studies included did not report the basis for the as-
sumed values of the population parameters. So the values
assumed for the key population parameters may be the
weakest part of the RCT design.
A frequently reported problem with publicly funded
RCTs is that the recruitment of participants is often slo-
wer or more difficult than expected, with many trials
failing to reach their planned sample size within the ori-
ginally envisaged trial timescale and trial-funding enve-
lope. A review of a cohort of 122 trials funded by the
United Kingdom (UK) Medical Research Council and
the NIHR Health Technology Assessment programme
found that less than a third (31%) of the trials achieved
their original patient recruitment target, 55/122 (45.1%)
achieved less than 80% of their original target and half
(53%) were awarded an extension [5]. Similar findings
were reported in a recently updated review [6]. Thus,
many trials appear to have unrealistic recruitment rates.
Trials that do not recruit to the target sample size within
the time frame allowed will have reduced power to de-
tect the pre-specified target effect size.
Thus the success of definitive RCTs is mainly dependent
on the availability of robust information to inform the de-
sign. A well-designed, conducted and analysed pilot orfeasibility trial can help inform the design of the definitive
trial and increase the likelihood of the definitive trial
achieving its aims and objectives. There is some confusion
about terminology and what is a feasibility study and what
is a pilot study. UK public funding bodies within the
NIHR portfolio have agreed definitions for pilot and feasi-
bility studies [7]. Other authors have argued against the
use of the term ‘feasibility’ and distinguish three types of
preclinical trial work [8].
Distinguishing features of pilot and feasibility studies
NIHR guidance states:
Feasibility studies are pieces of research done before a
main study in order to answer the question ‘Can this
study be done?’. In this context they can be used to esti-
mate important parameters that are needed to design
the main study [9]. For instance:
i) standard deviation of the outcome measure, which is
needed in some cases to estimate sample size;
ii) willingness of participants to be randomised;
iii) willingness of clinicians to recruit participants;
iv) number of eligible patients over a specific time
frame;
v) characteristics of the proposed outcome measure and
in some cases feasibility studies might involve
designing a suitable outcome measure;
vi) follow-up rates, response rates to questionnaires,
adherence/compliance rates, intracluster correlation
coefficients in cluster trials, etc.
Feasibility studies for randomised controlled trials may
themselves not be randomised. Crucially, feasibility stud-
ies do not evaluate the outcome of interest; that is left to
the main study.
If a feasibility study is a small RCT, it need not have
a primary outcome and the usual sort of power calcu-
lation is not normally undertaken. Instead the sample
size should be adequate to estimate the critical para-
meters (e.g. recruitment rate) to the necessary degree of
precision.
Pilot trials are a version of the main study that is run
in miniature to test whether the components of the main
study can all work together [9]. It will therefore resemble
the main study in many respects, including an assess-
ment of the primary outcome. In some cases this will be
the first phase of the substantive study and data from
the pilot phase may contribute to the final analysis; re-
ferred to as an internal pilot. Or at the end of the pilot
study the data may be analysed and set aside, a so-
called external pilot [10].
For the purposes of this paper we will use the term
pilot study to refer to the pilot work conducted to esti-
mate key parameters for the design of the definitive trial.
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RCT designs using an internal pilot study [11-14].
There is disagreement over what sample size should
be used for pilot trials to inform the design of definitive
RCTs [15-18]. Some recommendations have been devel-
oped although there is no consensus on the matter. Fur-
thermore, the majority of the recommendations focus
on estimating the variability of a continuous outcome
and relatively little attention is paid to binary outcomes.
The disagreement stems from two competing pressures.
Small studies can be imprecise and biased (as defined
here by comparing the median of the sampling distribu-
tion to the true population value), so larger sample sizes
are required to reduce both the magnitude of the bias
and the imprecision. However, in general participants
measured in an external pilot or feasibility trial do not
contribute to the estimation of the treatment effect in
the final trial, so our aim should be to maintain adequate
power while keeping the total number of subjects stu-
died to a minimum. Recently some authors have pro-
moted the practice of taking account of the imprecision
in the estimate of the variance for a continuous out-
come. Several suggest the use of a one-sided confidence
interval approach to guarantee that power is at least
what is required more than 50% of the time [15,18,19].
This paper aims to provide recommendations and
guidelines with respect to two considerations. Firstly,
what is the number of subjects required in an external
pilot RCT to estimate the uncertain critical parameters
(SD for continuous outcomes; and consent rates, event
rates and attrition rates for binary outcomes) needed to
inform the design of the definitive RCT with a reasonable
degree of precision? Secondly, how should these estimates
from the pilot study be used to inform the sample size
(and design) for the definitive RCT? We shall assume that
the pilot study (and the definitive RCT) is a two-parallel-
balanced-group superiority trial of a new treatment versus
control.
For the purposes of this work we assume that the sam-
ple size of the definitive RCT is calculated using a level
of significance and power argument. This is the ap-
proach that is currently commonly employed in RCTs;
however, alternative methods to calculate sample size
have been proposed, such as using the width of confi-
dence intervals [20] and Bayesian approaches to allow
for uncertainty [21-23].
Methods
Our aim is to demonstrate the variation in estimates of
population parameters taken from small studies. Though
the sampling distributions of these parameters are well
understood from statistical theory, we have chosen to
present the behaviours of the distributions through simu-
lation rather than through the theoretical arguments asthe visual representation of the resulting distributions
makes the results accessible to a wider audience.
Randomisation is not a necessary condition for esti-
mating all parameters of interest. However, it should be
noted that some parameters of interest during the feasi-
bility phase are related to the randomisation procedure
itself, such as the rate of willingness to be randomised,
and the rate of retention or dropout in each randomised
arm. In addition, randomisation ensures the equal distri-
bution of known and unknown covariates on average
across the randomised groups. This ensures that we can
estimate parameters within arms without the need to
worry about confounding factors. In this work we there-
fore decided to allow for the randomisation of partici-
pants to mimic the general setting for estimating all
parameters, although it is acknowledged that some pa-
rameters are independent of randomisation.
We first consider a normally distributed outcome mea-
sured in two groups of equal size. We considered study
groups of from 10 to 80 subjects using increments of five
per group. For each pilot study size, 10,000 simulations
were performed. Without loss of generality, we assumed
the true population mean of the outcome is 0 and the true
population variance is 1 (and that these are the same in
the intervention and control groups). We then use the es-
timate of the SD, along with other information, such as
the minimum clinically important difference in outcomes
between groups, and Type I and Type II errors levels, to
calculate the required sample size (using the significance
thresholds approach) for the definitive RCT.
The target difference or effect size that is regarded as
the minimum clinically important difference is usually
the difference in the means when comparing continuous
outcomes for the intervention with those of the control
group. This difference is then converted to a standardised
effect size by dividing by the population SD. More details
of the statistical hypothesis testing framework in RCTs
can be found in the literature [24,25].
For a two-group pilot RCT we can use the SD estimate
from the new treatment group or the control/usual care
group or combine the two SD estimates from the two
groups and use a pooled standard deviation (SDp) esti-
mated from the two-group specific sample SDs. For
sample size calculations, we generally assume the var-
iability of the outcome is the same or equal in both
groups, although this assumption can be relaxed and
methods are available for calculating sample sizes as-
suming unequal SDs in each group [26,27]. This is
analogous to using the standard t-test with two in-
dependent samples (or multiple linear regression), which
assumes equal variances, to analyse the outcome data
compared with using versions of the t-test that do not
assume equal variances (e.g. Satterthwaite’s or Welch’s
correction).
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ted and consider a number of different true population
proportions as the variation of proportion estimator is a
function of the true proportion. When estimating an
event rate, it may not always be appropriate to pool the
two arms of the study so we study the impact of estimat-
ing a proportion from a single arm where the study size
increases in steps of five subjects. We considered true
proportions in the range 0.1 to 0.5 in increments of 0.05.
For each scenario and sample size, we simulated the
feasibility study at least 10,000 times depending on the
assumed true proportion. For the binary outcomes,
the number of simulations was determined by requiring
the proportion to be estimated within a standard error
of 0.001. Hence, the largest number of simulations re-
quired was 250,000 when the true proportion was equal
to 0.5. Simulations were performed in Stata version 12.1
[28] and R version 13.2 [29].
Normally distributed outcomes
For each simulation, sample variances were calculated
for each group (s21 and s
2
2) and the pooled SD was calcu-
lated as follows:
SDp ¼
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
s21 þ s22ð Þ
2
 s
: ð1Þ
We also computed the standard error of the sample
pooled SD which is
se SDp
  ¼ SDpffiffiffiffiffiffiffiffiffiffiffiffiffiffi
2 n−1ð Þp ⋅ ð2Þ
To quantify the relative change in precision, we com-
pared the average width of the 95% confidence intervals
(WCI2n) for the SDp for study sizes of 2n with the aver-
age width when the study size was increased to 2(n + 5).
We use the width of the confidence interval as this pro-
vides a measure of the precision of the estimate.
Given the sampling distribution of the SD, its lower
and upper 95% confidence limits are given by:
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
2 n−1ð Þ
χ0:025;2 n−1ð Þ
s
SDp and
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
2 n−1ð Þ
χ0:975;2 n−1ð Þ
s
SDp
 !
; ð3Þ
and the relative percentage gain in precision is quanti-
fied as the reduction in 95% confidence interval width if
the sample size is increased by five per group:
WCI2n− WCI2 nþ5ð Þ
WCI2n
 
 100: ð4Þ
Bias is assessed by subtracting the true value from
each estimate and taking the mean of these differences.We also consider the impact of adjusting the SD esti-
mate from the pilot as suggested originally by Browne in
1995 [15]. Here a one-sided confidence limit is proposed
to give a corrected value. If we used the 50% one-sided
confidence limit, this would adjust for the bias in the es-
timate, and this correction has also been proposed when
using small pilots [17]. If we specify 50% confidence
then our power will be as required 50% of the time. Sim
and Lewis [18] suggest that it is reasonable to require
that the sample size calculation guarantees the desired
power with a specified level of confidence greater than
50%. For the sake of illustration, we will consider an 80%
confidence level for the inflation factor. So we require
the confidence interval limit associated with 80% confi-
dence above that value. Hence the inflation factor to
apply to the SDp from the pilot is:ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
2 n−1ð Þ
χ0:8;2 n−1ð Þ
⋅
s
ð5Þ
To consider the impact on power and planned sample
size, we need to state reasonable specific alternative hy-
potheses. In trials, it is uncommon to see large dif-
ferences between treatments so we considered small to
medium standardised effect sizes (differences between
the group means) of 0.2, 0.35 and 0.5 [30]. For each true
effect size of 0.2, 0.35 or 0.5, we divide by the SDp esti-
mate for each replicate, and use this value to calculate
the required sample size. For each simulated pilot study,
we calculate the planned sample size for the RCT assum-
ing either the unadjusted or adjusted SDp estimated
from the pilot. Using this planned sample size (where
the SDp has been estimated) we then calculate the true
power of the planned study assuming that we know that
the true population SDp is in fact 1.
Binary outcomes
We consider that the binary outcome will be measured
for one homogeneous group only. The following is re-
peated for each true population success probability. We
examined nine true success probabilities from 0.1 to 0.5
in intervals of 0.05. We considered 41 different pilot
study sizes ranging from 10 to 200 consisting of multi-
ples of five subjects. The subscripts i and j are used to
denote the true proportion and the pilot study size,
respectively. For each simulated pilot study of size nj,
the number of successes (Yij~ Bin(nj, θi)) in the simu-
lation nj are counted. First, the observed proportions, θ^ i ,
for each of the nine true success probabilities were calcu-
lated by:
θ^ i ¼ Y ijnj : ð6Þ
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using Wilson’s score [21] given by:
θ^ i þ z
2
α=2
2nj
 zα=2
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
θ^ i 1−θ^ ið Þþz
2
α=2
4nj
nj
s0
B@
1
CA
1þ z
2
α=2
nj
  ð7Þ
Second, this process was repeated for Ns (the number
of simulations needed to estimate the true success prob-
ability to within 0.1% of its standard error) and the aver-
age observed success probability for each of the nine
true success probabilities (θ) for a given fixed pilot size
were calculated as follows:
θ i ¼ 1Ns
XNs
k¼1θ^ ik ; ð8Þ
where θ^ ik is θ^ i for the kth simulated pilot study. Third,
due to the relatively small sample size of the pilot trials,
we computed the mean width of the 95% confidence
interval of the true success probability averaged over Ns
simulations using the Wilson’s score method [31] for a
fixed sample size, which is given by:
1
Ns
XNs
k¼1
2za=2
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
θ^ ik 1−θ^ ikð Þ þz
2
a=2
4nj
nj
s0
B@
1
CA
1þ z
2
a=2
nj
  : ð9ÞFigure 1 Multiple box and whisker plot of SDp estimates by pooled s
the SDp estimate for 10,000 simulations per pilot study size. The horizontalThe relative percentage gain in precision around the
true binomial proportion per increase of five study par-
ticipants is defined as before:
WCInj− WCInjþ5
WCInj
 !
 100: ð10Þ
As for the continuous outcomes, bias is assessed by
subtracting the true population value from each estimate
and taking the signed mean of these. We also report the
95% coverage probability [32].
Results and discussion
Normally distributed outcomes
Figure 1 is a multiple box and whisker plot of the result-
ing distributions of the sample SDp. Under our simula-
tions the true SD is equal to 1. Figure 1 clearly shows
that the spread of the estimates reduces as the pooled
sample size increases and the distribution of the esti-
mated SDp also becomes more symmetric as the pooled
sample size increases. So the bias and skew is more
marked for smaller sample sizes. The direction of the
bias means that the SD tends to be underestimated.
Once the total sample size is above 50 the average bias
becomes negligible and is less than 0.005 below the true
value. However, what is more noticeable is the large
variation in the sampling distribution for the smaller
sample sizes and considerable sampling variation re-
mains even with a large sample size.
Figure 2 shows the percentage gain in precision (the
width of the confidence interval for the SDp) when add-
ing ten more participants to the sample (five to eachample size of the pilot study. The vertical axis shows the value of
axis is graduated by the pooled pilot study size.
Figure 2 Percentage gain in precision of SDp on increasing the pooled sample size. This shows the relative reduction in the average width
of the confidence interval when an additional five subjects are added to a group.
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the relative gain in precision (while always positive) de-
creases with increasing sample size. With a total sample
size of 70, there is a less than 10% gain in precision
when adding further participants to the study size. So in
terms of good precision and minimal bias (for a continu-
ous outcome) a total sample size of 70 seems desirable
for a pilot study.
Figure 3 shows the distribution of true power for the
planned sample sizes for the specific alternative effectFigure 3 Distribution of planned RCT study power when using the SD
used to calculate the true power if SD = 1 is assumed. The graph shown is
shows the size of the two-arm pilot study.size of 0.2, assuming we require 90% power at the 5%
two-sided significance level. The true power distribution
for the other effects sizes is very similar (it can be shown
that conditional on the estimated SD from the pilot, the
distributions should be the same but rounding up to in-
tegers causes slight changes at small sample sizes). As
anticipated, this figure shows a large variation in power
for the smaller sample sizes. However, even with the
relatively small pilot sample size of 20, the planned stud-
ies do have at least 80% power to detect the target effectp estimate derived from the pilot study. The planned study size is
for a true effect size of 0.2. The vertical axis is true power. The x-axis
Figure 4 (See legend on next page.)
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Figure 4 Distribution of planned sample sizes using crude SDp estimates and adjusting for a specified level of confidence. (a) Effect
size = 0.2. (b) Effect size = 0.35. (c) Effect size = 0.5. The upper part of each graph shows the distribution of planned sample sizes by pilot study
size. The lower part shows the same but using the inflation adjustment to guarantee the specified power with 80% confidence. The x-axis shows
the planned sample size and the vertical axis shows the pilot study size. The dashed vertical line shows the sample size associated with a true
power of 90% and the dotted line for 80%.
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than 75% of the time. Figure 3 also shows that the true
power frequently exceeds 90% but the cost of this higher
power in terms of total participants cannot be quantified
from this figure. By contrast Figure 4 is able to show the
‘cost’ of the higher power translated into the sample size
scale.
Figure 4 shows the distribution of the planned sample
size when using the estimated SDp from the pilot (with
and without inflation of the SDp). It can be seen that the
overall shape of these plots is similar for all three effects
sizes, but the planned sample sizes are proportionately
higher as the effect size reduces. Figure 4a shows the
sample size (for a true difference between the means of
0.2) using the unadjusted SDp (upper plot) and the in-
flated SDp (lower plot). Using the inflated SDp means we
have specified that we want our planned study to have
90% power with 80% confidence or certainty. By com-
paring these two plots and superimposing the sample
size of 1,052, which is what we would actually need to
detect an effect size of 0.2 with 90% power and 5% two-
sided significance when the true SD is known to be
equal to 1, you can readily see the effect of the infla-
tion factor. Figures 4b,c present the same contrasts as
Figure 4a but for a true difference between the means of
0.35 and 0.5, respectively. The main impact of the infla-
tion factor is to guarantee that 80% of the planned stu-
dies are in fact larger than they need to be, and for the
smaller pilots this can be up to 50% larger than neces-
sary. If only the unadjusted crude estimates from the
pilot are used to plan the future study, though we aim
for at least 50% of studies to be powered at 90%, inspec-
tion of the percentiles shows that that the planned sam-
ple size delivers at least 80% power with 90% confidence,
when a pilot study of at least 70 is used. Researchers
need to consider carefully the minimum level of power
they are prepared to tolerate for a worst-case scenario
when the population variance is overestimated.
Figure 5 adds the size of the pilot study to the planned
study size so the distribution of the overall number of
subjects required can be seen. The impact of the infla-
tion factor now depends on the true effect size. If we are
planning to use the inflation factor then when the effect
size is 0.5 a pilot study of around 30 is optimal. How-
ever, the same average number of subjects would result
using unadjusted estimates from a pilot study of size 70,
and this would result in a smaller variation in plannedstudy size. For the effect size of 0.2 then the optimal
pilot study size if applying the inflation factor is around
90, but this optimal size still results in larger overall
sample sizes than just using unadjusted estimates from
pilot studies of size 150.
Binary outcomes
The sampling distribution when estimating a proportion
is a function of the true population proportion so it
seems unwise to estimate this from a pooled group un-
less it is a measure independent of treatment group and
there is a strong assumption of equality between groups.
We have explored the sampling distributions of the pro-
portions in increments of five rather than ten as we
allow the possibility that this may be estimated from one
arm. As statistical theory predicts the sampling variation
is largest when the true proportion is 0.5 and reduces as
the true proportion becomes more different from 0.5,
we show the results for the two most extreme propor-
tions considered, i.e. 0.1 and 0.5 (Figure 6). When the true
proportion is 0.1 the sampling distribution is slightly
skewed with a tendency to underestimate the true value
even when uneven pilot arm sizes are used. However,
when the true proportion is 0.5 there is no systematic bias
in under- or overestimating the parameters from the pilot.
Most of the fluctuation is due to deriving estimates from a
sample size where the true proportion is not a possible
outcome (e.g., if the true proportion is 0.5 but the sample
size is 25, then the closest you can observe to the true
value is 12/25 or 13/25). Once the pilot sample size is 60
or more then these fluctuations settle down. The relative
percentage gain in the precision of estimates is formally
presented in Figure 7, where the average width of the 95%
confidence intervals for the proportion are compared with
the average confidence interval width if another five sub-
jects were added to the sample. This relative percentage
gain in precision is shown for true proportions 0.1 and
0.5. For the continuous outcomes we suggested a cut-off
of 10% as a threshold. For the binary outcomes we use the
5% threshold as we are moving in steps of five rather than
ten. The relative percentage gain in the precision graph
crosses the 5% threshold when the sample size is 55 to 60
and crosses the 3% threshold when the sample size is 100.
Figure 8 shows the coverage probability for five of the true
proportions as sample size increases. This shows how
frequently the 95% confidence interval contains the true
value. This graph shows considerable fluctuations. Once
Figure 5 (See legend on next page.)
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Figure 5 Distribution of total sample size required when using pilot sample derived SDp estimated with and without inflation. (a)
Effect size = 0.2. (b) Effect size = 0.35. (c) Effect size = 0.5. This figure is similar to Figure 4; however, now the total sample size includes the pilot
study size. The dashed and dotted vertical lines represent the sample size required for 90% and 80% power, respectively, if the true SD were
known and the pilot study were not necessary.
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provement in the coverage probability for the true propor-
tions considered here.
Conclusions
Our simulated data visually demonstrate the large sam-
pling variation that is the main weakness when estimating
key parameters from small sample sizes. Small samplesFigure 6 Distribution of estimated event rates on increasing sample s
rate of 0.5 (b).sizes do lead to biased estimates, but the bias is negligible
compared to the sampling variation. When we examine
the relative percentage gain in precision by adding more
subjects to the sample, our data suggest that a total of at
least 70 may be necessary for estimating the standard
deviation of a normally distributed variable with good
precision, and 60 to 100 subjects in a single group for
estimating an event rate seems reasonable. Treatment-ize. Distributions for a true event rate of 0.1 (a) and a true event
Figure 7 Distribution of relative gain in precision for binary outcomes as pilot study size increases. This graph compares the width of the
confidence intervals for n + 5 subjects and n subjects. This is scaled by the width of the interval when there are n subjects.
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two groups, so in many cases our recommended sample
size will be the total sample size. On average when the de-
finitive RCT is planned using an estimate from a pilot
study there will be a tendency for the planned study to be
underpowered. However, if the definitive RCT is planned
for a continuous outcome requiring a power of 90% then
the true power will be 80% with at least 76% assurance
provided the estimates come from a pilot with at least 20
subjects. We considered three realistic effect sizes of 0.2,
0.35 and 0.5 of a standard deviation to evaluate the impactFigure 8 Distribution of mean coverage probability by true proportioof adjusting for the anticipated uncertainty in the estimate
from the pilot when calculating the sample size for the
planned RCT as was recently suggested [18]. For all of the
effect sizes considered, it is not efficient to use small pilots
and apply the inflation adjustment, as this will result in
larger sample sizes (pilot plus main study) in total. Further,
we only considered sample sizes planned when requiring
90% power, and examine the conditional power assuming
we know the true alternative. On average using imprecise
estimates but requiring high power will result in ac-
ceptable power with much less ‘cost’ as measured by totaln and pilot sample size.
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http://www.trialsjournal.com/content/15/1/264sample size. Hence, it is actually more efficient to use a
large external pilot study to reduce the variation around
the target power for the definitive RCT.
The implication of using estimates of key parameters
from small pilot studies is the risk of both over- and
underpowered studies. While overpowered studies may
not seem such an acute problem, they are potentially a
costly mistake and may result in a study being judged as
prohibitively large. This would seem to be an argument
in favour of utilising internal pilot studies, but an in-
ternal pilot requires the key design features of the trial
to be fixed, so any change in measurement of the treat-
ment effect following an internal pilot will lead to ana-
lysis difficulties.
A major and well-documented problem with published
trials is under recruitment, where there is a tendency to
recruit fewer subjects than targeted. One reason for un-
der recruitment may well be that event rates such as re-
cruitment and willingness to be randomised cannot be
accurately estimated from small pilots, and in fact in-
creasing the pilot size to between 60 and 100 per group
may give much more reliable data on the critical recruit-
ment parameters.
In reality, when designing external pilot trials, there is
a need to balance two competing issues: maximising the
precision (of the critical parameters you wish to esti-
mate) and minimising the size of the external pilot trial,
which impacts on resources, time and costs. Thus there
is a trade-off between the precision (of the estimates of
the critical parameters) and size (number of subjects) of
the pilot study. When designing external pilot trials, re-
searchers need to understand that they are trading off
the precision of the estimates against the total sample
size of the definitive study when they decide to have an
external pilot study with a small sample size.
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